More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Oculis Shuts Down Phase III Trial of OCS-01 Due to Third-Party Administrative Error
Author: Jennie Crabbe
Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and pain after a third-party administrative error affected the conduct of the study and prevented analysis of the results. The company said, however, that the US FDA had assured it that data from the completed OPTIMIZE-1 Phase III trial, along with Phase II results and safety data from trials of OCS-1 i...
